Preclinical and/or clinical results demonstrate that PI3K, AKT, mTOR, MEK and FAK inhibitors (i), alone or in combination, display therapeutic potential against thyroid carcinoma cells. Here, MAP2K7 is linked to thyroid gland carcinoma.